www.stltoday.com

www.stltoday.com
Share

www.stltoday.com

 •  October 13

A recent study raises serious questions about the price and effectiveness of Mallinckrodt’s highest revenue-generating drug, H.P. Acthar. A JAMA Internal Medicine study published in September found the drug has cost Medicare, the taxpayer-funded health care plan for seniors, more than $1 billion over a five-year period. And in 2015, it was the 52nd...

www.stltoday.com

 •  August 19

FRIDAY, Aug. 18, 2017 (HealthDay News) -- The U.S. Food and Drug Administration may shorten the list of caveats for drugs you see advertised on television. Prescription drug makers must now mention all benefits and risks in direct-to-consumer advertising, presenting viewers with a litany of potential harms, both major and minor. But a new approach...

www.stltoday.com

 •  August 16

TUESDAY, Aug. 15, 2017 (HealthDay News) -- Many cutting-edge drugs and updated medical devices are not receiving the rigorous scientific scrutiny needed to ensure their safety and effectiveness, two new studies contend. Medications fast-tracked to market under the U.S. Food and Drug Administration's "accelerated approval" process are not receiving...

www.stltoday.com

 •  August 2

TUESDAY, Aug. 1, 2017 (HealthDay News) -- A drug used for some cases of kidney disease can raise the risk of serious infections, researchers say. A clinical trial was stopped early when researchers discovered that patients on the drug -- a corticosteroid called methylprednisolone -- suffered a concerning number of serious side effects. Most often,...

www.stltoday.com

 •  July 31

NEW YORK • Pharmacy benefit manager Express Scripts Holding Co. said on Monday it would favor drugmaker Mylan Inc.'s versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies. The nation's largest pharmacy benefit manager said it was excluding alternatives to the auto-injector made by Impax Laboratories...

www.stltoday.com

 •  July 10

When 76 deaths were traced to a lightly regulated compounding pharmacy, the calamity was shocking enough to prompt quick action by Congress. The Drug Quality and Security Act of 2013 brought Food and Drug Administration oversight to any pharmacy that mass-produces a drug, as New England Compounding Center in Framingham, Mass., was doing when its...

www.stltoday.com

 •  July 8

When 76 deaths were traced to a lightly regulated compounding pharmacy, the calamity was shocking enough to prompt quick action by Congress. The Drug Quality and Security Act of 2013 brought Food and Drug Administration oversight to any pharmacy that mass-produces a drug, as New England Compounding Center in Framingham, Mass., was doing when its...

www.stltoday.com

 •  June 15

Dear Readers • Nearly 1 in 3 drugs approved by the Food and Drug Administration (FDA) between 2001 and 2010 have had a safety issue detected in the years after approval, according to a report by Dr. N.S. Dowling and associates published in the Journal of the American Medical Association. While most of the safety concerns are not serious enough to...

www.stltoday.com

 •  June 5

SUNDAY, June 4, 2017 (HealthDay News) -- A twice-daily pill could help some advanced breast cancer patients avoid or delay follow-up sessions of chemotherapy, a new clinical trial reports. The drug olaparib (Lynparza) reduced the chances of cancer progression by about 42 percent in women with breast cancer linked to BRCA1 and BRCA2 gene mutations,...

www.stltoday.com

 •  May 20

FRIDAY, May 19, 2017 (HealthDay News) -- A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. Gleevec (imatinib) reduced the "twitchiness" of airways, making them less likely to reflexively constrict when exposed to an allergen or asthma trigger, said senior researcher Dr. Elliot Israel. "We showed we...